# Quad-Agonist GLP Drugs for Type 2 Diabetes and Heart Failure

Canonical source: https://retacompare.com/research/quad-agonist-glp-drugs-for-type-2-diabetes-with-heart-failure

Therapeutic Applications · 2026-05-02


    Emerging quad-agonist therapies targeting GLP-1 receptors show promise for addressing Type 2 diabetes (T2D) and heart failure with preserved ejection fraction (HFpEF). These multi-agonists aim to enhance metabolic control while potentially providing cardiovascular benefits.

 The big picture

The landscape of obesity and metabolic disease management is evolving rapidly, particularly in the wake of successful agents like Retatrutide, which has demonstrated efficacy in weight management and glycemic control. As the pharmaceutical pipeline expands, quad-agonists are emerging as a potential next step in addressing the complex interplay between Type 2 diabetes (T2D) and heart failure with preserved ejection fraction (HFpEF). This combination of conditions presents unique challenges, as traditional treatments may not adequately address both metabolic and cardiovascular needs simultaneously. Quad-agonists, designed to target multiple receptors, aim to bridge this gap by enhancing metabolic pathways while also improving cardiovascular outcomes, a crucial consideration given the high prevalence of HFpEF among T2D patients.

 How it works

Quad-agonists are designed to activate multiple receptor pathways, including GLP-1, GIP, glucagon, and potentially others, depending on the specific agent. This multifaceted approach is hypothesized to not only improve glycemic control but also promote weight loss and enhance cardiovascular health. The rationale behind this design is grounded in the understanding that obesity and T2D are multifactorial conditions, and targeting multiple pathways may yield synergistic effects. For instance, GLP-1 receptor activation has been associated with increased insulin secretion, reduced glucagon levels, and delayed gastric emptying, all of which contribute to improved glycemic control. Additionally, the inclusion of glucagon receptor agonism may aid in weight loss through enhanced energy expenditure and appetite regulation. Current investigational agents, such as those from companies including Hanmi, Amgen, and Boehringer Ingelheim, are exploring these mechanisms to establish a more comprehensive treatment approach.

 Key points at a glance

Quad-agonists aim to target multiple pathways to improve outcomes in T2D and HFpEF.

Current research includes candidates like HM15275 (Hanmi) and MariTide (Amgen).

These agents are hypothesized to enhance metabolic control and provide cardiovascular benefits.

GLP-1 receptor activation contributes to insulin secretion and appetite regulation.

Potential for improved patient adherence due to the dual benefits of weight loss and glycemic control.

Research is ongoing to determine long-term efficacy and safety profiles.

 Where this fits in the pipeline

Several quad-agonist candidates are currently in various stages of clinical development. For example, HM15275 from Hanmi is in early-phase trials, while Amgen's MariTide is also under investigation. Other candidates, such as Survodutide from Boehringer Ingelheim, are being studied for their potential in managing both T2D and associated cardiovascular risks. While specific clinical trial results are pending, the focus remains on establishing the safety and efficacy of these multi-agonists. The timeline for regulatory approval is uncertain, but given the urgency of addressing T2D and HFpEF, expedited pathways may be pursued.

 What it could mean for patients

If successful, quad-agonist therapies could significantly impact patient management by providing a dual approach to treating T2D and HFpEF. This could lead to improved glycemic control, weight loss, and potentially reduced cardiovascular events, addressing a critical gap in current treatment paradigms. However, the actual clinical impact will depend on rigorous testing and validation in diverse patient populations, particularly those with existing heart failure.

 Open questions and what we don't yet know

Despite the promising potential of quad-agonists, several questions remain unanswered. Key uncertainties include the long-term safety profiles of these agents, potential side effects, and their overall efficacy compared to existing treatments. Additionally, the complexity of receptor interactions raises concerns about the predictability of outcomes. Regulatory hurdles may also pose challenges, as the approval process for multi-agonist therapies is less established compared to traditional single-target drugs.

 Bottom line

Quad-agonist therapies represent a promising frontier in the treatment of Type 2 diabetes and heart failure, with the potential to address both metabolic and cardiovascular needs. Ongoing research will be critical in determining their place in clinical practice.

 This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources